Article: ViroPharma told Vanocin not focus of OGD meeting by FDA.(Brief article)

Pennsylvania, USA-based ViroPharma has been informed by the US Food and Drug Administration that the July 23 meeting of its Advisory Committee for Pharmaceutical Science and Clinical Pharmacology is not intended to discuss specifically ViroPharma's Vancocin (vancomycin hydrochloride capsules) or any other drug products.

The FDA has informed the US firm that the Office of Generic Drugs will only present for the Committee's consideration issues of general applicability to all locally-acting drugs that treat gastrointestinal ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!